Tarlatamab + durvalumab as 1L maintenance in ES-SCLC: DeLLphi-305 met its OS endpoint at an interim analysis, Amgen said on 8 Sep. Our faculty member Jacob Sands (@sands_jacob) presents them at #ESMO26, LBA3, Sat 24 Oct, 17:18, Hall 6. Calendar file: https://t.co/T7PqGHFhac In the hall or online? @myESMO